DBVT News and Press, DBV Technologies S.A. From 08/01/20

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Volatility watch: Short interest is in an uptrend for Vale (NYSE: VALE ) , Nokia (NYSE: NOK ) , United Airlines (NASDAQ: UAL ) , Micron Technology (NASDAQ: MU ) and Denbury Resources (NYSE: DNR ) , while GameStop (NYSE: GME ) , National Beverage (NASDAQ: FIZZ ) and Dillard's (NYSE:...

Montrouge, France, July 31, 2020 DBV Technologies Reports First Half 2020 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2020 financial results. The interim ...

Monthly information regarding the total number of voting rights and  total number of shares of the Company as of June 30, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Cod...

DBV Technologies Reports Positive Extension Study Results DBV Technologies (DBVT) reported positive results from its open label extension of the Phase 3 study. The data showed that the participants underwent sustained clinical benefit with an extra two years of treatment with Viaskin Pea...

DBV Technologies ( DBVT ) announces results from a three-year open-label extension, PEOPLE , of the Phase 3 PEPITES study evaluating Viaskin Peanut in children with peanut allergy. The data were just published in The Journal of Allergy and Clinical Immunology.  More news on: D...

Montrouge, France, July 7, 2020 DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology PEOPLE is the largest long-term peanut allergy immunotherapy trial to date and showed fav...

DBV Technologies (NASDAQ: DBVT) , a biopharmaceutical company based in France, provided a business update today regarding Viaskin, a potential peanut allergy treatment the company developed that is currently being reviewed by the U.S. Food and Drug Administration (FDA). DBV Technologies expre...

Milestone Scientific (NYSEMKT: MLSS )  -20%  after pricing equity offering. More news on: Milestone Scientific Inc., DBV Technologies S.A., Ideanomics, Inc., Stocks on the move, , Read more ...

Montrouge, France, June 26, 2020 DBV Technologies Provides Operational and Business Update BLA review of Viaskin Peanut for the treatment of peanut allergy in children ages 4-11 years ongoing Company to immediately initiate restructuring plan to extend cash runway while awaitin...